ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Depreciation & Amortization (CF) of $397000.0 for Q1 2026, down 4.8% sequentially from $417000.0 in Q4 2025, and up 41.79% YoY from $280000.0 in Q1 2025.
ARS Pharmaceuticals (SPRY) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $397000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 41.79% year-over-year to $397000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 247.54% YoY) and the FY2025 annual result came in at $1.4 million, up 1630.38% from the prior year.
- Depreciation & Amortization (CF) slipped to $397000.0 in Q1 2026 per SPRY's latest filing, from $417000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $417000.0 in Q4 2025 and troughed at -$37000.0 in Q2 2022.
- A 5-year average of $140812.5 and a median of $64500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) sank 117.7% in 2022, then surged 2445.45% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $14000.0 in 2022, then jumped by 614.29% to $100000.0 in 2023, then tumbled by 71.0% to $29000.0 in 2024, then soared by 1337.93% to $417000.0 in 2025, then declined by 4.8% to $397000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $397000.0, $417000.0, and $391000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | 416,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 416,000.00 |
| Jun 30, 2026 | 416,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Mar 31, 2026 | 397,000.00 |
| Dec 31, 2025 | 417,000.00 |
| Dec 31, 2025 | 417,000.00 |
| Sep 30, 2025 | 391,000.00 |
| Sep 30, 2025 | 391,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Jun 30, 2025 | 279,000.00 |
| Mar 31, 2025 | 280,000.00 |
| Mar 31, 2025 | 280,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Dec 31, 2024 | 29,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |